The present invention concerns vlpt immunoreactive compositions for e. Chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for e. Chaffeensis vlpt are disclosed.

The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or nkt agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing ...

Provided herein are (1) a method of mixing an aluminum salt-adsorbed immunogen with a monophosphoryl lipid a (mpla)-containing liposome (l(mpla)), and (2) the resulting immunogenic composition. The resulting immunogenic composition has an enhanced immunostimulation potency compared with either a composition comprising the uncapsulated immunogen mixed with the l(mpla) or the aluminum salt-adsorbed immunogen alone.

Synthetic hiv envelope proteins, vectors and compositions thereof, and methods for inducing protective immunity against human immunodeficiency virus (hiv) infection are described. Viral expression vectors encoding the synthetic hiv envelope proteins can be used in vaccines to provide improved protective immunity against hiv.

The present invention relates to a thermostable freeze dried rotavirus vaccine formulation and the process of preparing the same. More specifically the present invention discloses multivalent thermostable liquid, powder or cake based rotavirus vaccine formulation prepared using the freeze drying process, such that the said vaccine formulation possess improved heat-stability, easy to use and transport and highly affordable thereby meeting ...

An aspect of the present invention is directed towards dna plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a dna plasmid and a pharmaceutically acceptable excipient. The dna plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit ...

Regions of bacillus anthracis protective antigen are provided representing epitopes recognized by antibodies in subjects that have acquired immunity to bacillus anthracis infection. The recognition of these epitopes correlates with autoimmunity in a subject. Also provided are vaccines that include at least one of these epitopes that when administered to a subject provide improved acquired immunity.

The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ert) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, ...

A method of treating a synucleinopathy with a peptide (c)dqpvlpd (seq id no: 59), (c)dmpvlpd (seq id no: 60), (c)dspvlpd (seq id no: 61), (c)dqpvlpdn (seq id no: 64), (c)dmpvlpdn (seq id no: 65), (c)dspvlpdn (seq id no: 66), (c)hdrpvtpd (seq id no: 70), (c)drpvtpd (seq id no: 71), (c)dvpvlpd (seq id no: 72), (c)dtpvypd (seq id no: 73), (c)...

The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.

A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids include compounds of formula i wherein n is 0 or 1; r is hydrogen or hydroxyl; and y is hydrogen or a sulfate group, at least ...

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous ...

The present invention provides compositions and methods for enhancing immunogenicity of polysaccharide antigens. Immunogenic compositions and vaccines comprising polysaccharide-protein conjugates comprising a chimeric carrier protein having a universal epitope are provided. Methods of preparing the compositions, and methods for treating or preventing bacterial infections are further provided. The compositions and methods are useful for enhancing immune response in young children, ...

The invention provides human papillomavirus (hpv) antigen formulations which show increased antigen stability. More specifically, the invention provides stable hpv formulations comprising hpv virus-like particles (vlps) bound to an aluminum salt adjuvant and further comprise a combination of sucrose and mannitol. The vaccine formulations of the invention are stable following freeze-thaw and freeze-drying. Also provided are lyophilized and frozen hpv ...

Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in streptococcus pneumoniae. The antigens may be used therapeutically or prophylactically.

The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method ...

The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (ifn) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine ns1 gene that diminish or eliminate the ability of the ns1 ...

The present invention relates to chimeric pestiviruses having utility as immunogenic compositions and vaccines. Also described herein are methods and kits for treating or preventing the spread of bovine viral diarrhea virus infection, as well as methods and kits for differentiating between vaccinated and wild-type infected animals.

Improved anti-hpv immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus hpv39 e6e7 and hpv45 e6e7. Pharmaceutical composition, recombinant vaccines comprising dna plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against hpv are disclosed.

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp. Subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of mycoplasma spp. In pigs. The vaccine can comprise ...

The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding ...